VERAXA Biotech AG (NASDAQ: VRXA) has achieved a significant regulatory milestone, receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI) that supports the development strategy for its lead BiTAC(R)-TCE program. The feedback, announced on July 20, provides early guidance on the company's biological rationale, safety assessments, and non-clinical development plan, helping to reduce uncertainty as the company prepares for clinical studies (https://ibn.fm/zBiDU).
The BiTAC(R)-TCE platform represents a novel class of bispecific T-cell engagers designed to harness the immune system to target and eliminate cancer cells. VERAXA's lead candidate previously demonstrated encouraging preclinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, highlighting its potential in oncology. The regulatory feedback from PEI, a key authority for biological products in Germany, is expected to streamline the path toward first-in-human trials by aligning the company's approach with regulatory expectations on safety and tolerability.
Scientific Advice procedures enable drug developers to consult with regulatory experts before initiating clinical trials, offering insights that can mitigate risks in development. For VERAXA, this guidance validates the biological rationale behind its BiTAC(R)-TCE candidate and provides clarity on the non-clinical studies required to support an Investigational New Drug (IND) application. The company believes this early engagement reduces development uncertainty, allowing for more efficient resource allocation and trial design.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. With the PEI's feedback, VERAXA is better positioned to navigate the complex regulatory landscape and accelerate its lead program toward clinical evaluation.
The positive regulatory interaction underscores VERAXA's commitment to developing innovative cancer therapies and highlights the potential of its BiTAC(R)-TCE platform to address unmet medical needs. As the company moves forward, it will leverage this guidance to finalize its preclinical package and engage with additional regulatory bodies as needed. Investors and stakeholders can track further updates in the company's newsroom at https://ibn.fm/VRXA.
